Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise Nott

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Vaccines|June 24, 2022
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from AustraliaDaphne Day, Lisa Grech, Mike Nguyen, et al.
The New England Journal of Medicine|June 3, 2022
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerJeanne Tie, Joshua D Cohen, Kamel Lahouel, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trialJohn W K Chia, Eva Segelov, Yanhong Deng, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Nature Communications|May 31, 2023
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapyMarjan M Naeini, Felicity Newell, Lauren G Aoude, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
The Lancet. Gastroenterology & Hepatology|February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trialDerek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Vaccines|June 24, 2022
Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from AustraliaDaphne Day, Lisa Grech, Mike Nguyen, et al.
The New England Journal of Medicine|June 3, 2022
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon CancerJeanne Tie, Joshua D Cohen, Kamel Lahouel, et al.
BMC Cancer|January 29, 2025
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary originAnna Ugalde, Richard W Tothill, Stephen Quinn, et al.
The Lancet. Gastroenterology & Hepatology|January 17, 2025
Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trialJohn W K Chia, Eva Segelov, Yanhong Deng, et al.
Journal of Cancer Policy|November 26, 2023
A tailored approach to horizon scanning for cancer medicinesJennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Nature Communications|May 31, 2023
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapyMarjan M Naeini, Felicity Newell, Lauren G Aoude, et al.
Pageof 6